Study Treatment Administration Details regarding preparation and administr ation are provided in site training materials. All Parts: BMS-986226 AdministrationXUse vials assigned per IRT. Safety Cohort and Part A BMS-986226 will be administered every 4 weeks on the first day of each cycle Revised Protocol No.: 04 Date: 31-May-2019 34 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS aEOT is defined as the visit where a decision is made to discontinue the participant from treatment. bFor participants who complete all scheduled cycles of therapy, the EOT visit will be the same as the last scheduled an d completed on-treatment visit (eg, Cycle 6 Day 175) and the start of the Week 1 safety follow-up visit. cFor participants who do not complete all scheduled cycles of therapy, the EOT visit will be the most recent on-treatment vi sit (with all available safety and response data) and does not need to be repeated, and it will be considered the start of the Week 1 safety follow-up visit. Abbreviations: AE = adverse event; D1 = Day 1; C = Cycle; CBC = complete blood count; ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; hCG = human chorionic gonadotropin; IRT = Interactive Re sponse Technology; min = minutes; PE = physical examin ation; PK = pharmacokinetic; Q12W = every 12 weeks; T3 = triiodothyronine; T4 = thyroxi ne; TSH = thyroid-stimulating hormone; WOCBP = women of c hildbearing potential. Revised Protocol No.: 04 Date: 31-May-2019 35 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-5: Additional Treatment Fo llow-up Procedural Outline (CA021002) ProcedureSafety Follow-upaSurvival/Response Long-term Follow-up FU 1 30 days (±±7 days) FU 2 60 days (±7 days)FU 3 100 days (±7 days)Begins After Completion of Safety Follow-up Q12W ( ±2 weeks) Until 2 years After Last Dose of Study TreatmentNotes Safety Assessments PE XXX Symptom-directed only. ECOG Performance StatusXXX E C O G score (Appendix 7) Vital Signs X X X See note in Table 2-1 .